We are pleased to announce that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a favorable opinion on Holoclar, the first stem cell treatment approved in Europe.
Holoclar is produced in Modena at the labs of Holostem Terapie Avanzate S.r.l, a subsidiary of Chiesi Farmaceutici.
Holoclar is a cell treatment based on autologous blast cell cultures from the limbal stem cells of the eyes. These cultures are implanted and regenerate a permanent functional corneal epithelium after an ocular burn, allowing vision to be restored.
Together with Glybera, the first gene therapy approved by the European Medicines Agency for the treatment of Lipoprotein Lipase Deficiency (LPLD), Holoclar strengthens our special treatments by strengthening our business model for rare and very rare diseases.
“Chiesi believes in innovation and research and has found ground for it in Holostem” , said Graziella Pellegrini, Director of Research and Development of Holostem Terapie Avanzate S.r.l. “This important success again proves that our efforts lead to great results”.
“We are proud of Holoclar, as it is an important milestone for our companies and the history of Medicine”, commented Andrea Chiesi, R&D Project and Portfolio Management of Chiesi Farmaceutici and CEO of Holostem Terapie Avanzate S.r.l. “Regenerative Medicine is today a reality that arises from the collaboration of Chiesi Farmaceutici with Holostem and opens the door to a new branch of medicine”.